Cargando…
ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma
BACKGROUND: Previous studies have shown that aldolase B (ALDOB) might play controversial roles in multiple types of cancer, which could act as a cancer-promoting factor or a cancer-inhibiting factor depending on the subtype of the cancer. However, the role of ALDOB in clear cell renal cell carcinoma...
Autores principales: | Shao, Yuan, Wu, Bo, Yang, Zhen, Liu, Zihao, Ma, Yuan, Huang, Hua, Liu, Yang, Wang, Zeyuan, Hu, Weijing, Wang, Yong, Niu, Yuanjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170270/ https://www.ncbi.nlm.nih.gov/pubmed/37181232 http://dx.doi.org/10.21037/tau-22-743 |
Ejemplares similares
-
Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer
por: He, Jun, et al.
Publicado: (2016) -
Prognostic values of ALDOB expression and (18)F-FDG PET/CT in hepatocellular carcinoma
por: Jia, Wenzhi, et al.
Publicado: (2022) -
ALDOB plays a tumor-suppressive role by inhibiting AKT activation in gastric cancer
por: Peng, Chaozhong, et al.
Publicado: (2023) -
LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma
por: Yang, Chunxiu, et al.
Publicado: (2021) -
Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma
por: Liu, Yankuo, et al.
Publicado: (2023)